Last updated: February 15, 2026
Overview:
NDC 29300-0132 corresponds to Lenvatinib, marketed as Lenvima. Approved by the FDA in 2015, Lenvatinib is an oral multikinase inhibitor primarily used for thyroid cancer, hepatocellular carcinoma (HCC), renal cell carcinoma, and other indications.
Market Size and Therapeutic Use
| Indication |
Estimated Global Market (USD, 2022) |
2021 Prescription Volume |
Major Competitors |
| Thyroid cancer |
$600 million |
10,000+ patients |
Sorafenib, Pazopanib |
| HCC (hepatocellular carcinoma) |
$1.2 billion |
20,000+ patients |
Sorafenib, Regorafenib, Cabozantinib |
| Renal cell carcinoma |
$900 million |
15,000+ patients |
Sunitinib, Pazopanib, Axitinib |
The global market for Lenvatinib is accelerating due to expanding indications and increased diagnosis rates. The drug holds approximately 60% share within the multikinase inhibitor segment for certain cancers.
Market Dynamics
-
Growth Drivers:
- Unmet needs in thyroid and liver cancers.
- Expansion into endometrial carcinoma (approved in 2021).
- Increasing adoption in combination therapies.
-
Challenges:
- Price sensitivity in emerging markets.
- Competition from newer therapies with improved efficacy or safety profiles.
- Patent exclusivity expiring for certain formulations in 2025.
Pricing Trends and Projections
Current Pricing (U.S.):
| Formulation |
Average Wholesale Price (AWP) |
Estimated Monthly Cost |
Notable Notes |
| 4 mg capsules |
~$600 per 30 capsules |
~$6,000 |
Based on list price; actual payer price typically lower due to negotiations |
| 10 mg capsules |
~$850 per 30 capsules |
~$8,500 |
Higher-dose formulations show proportionally higher prices |
Pricing Comparison with Competitors:
| Drug |
Indication |
Typical annual cost (USD) |
Market positioning |
| Sorafenib |
HCC, renal cell carcinoma |
~$50,000 |
Slightly lower price, broader indication coverage |
| Lenvatinib |
Multiple solid tumors |
~$70,000 |
Premium due to expanded indications and specific efficacy profiles |
Projected Price Trends (Next 3–5 Years):
- Moderate Decrease: Price reductions of 10-15% are expected in mature markets due to patent expiration and increased competition.
- Premium Segments: Prices in emerging markets may stabilize or decline marginally, with discounts of 20-30% compared to U.S. pricing.
- Combination Therapy Impact: Use in combination regimens (e.g., with Pembrolizumab) may maintain or slightly increase per-unit treatment costs by enabling higher dosing or prolonged therapy durations.
Potential Price Effects of Patent Expiry and Biosimilars:
- Patent expiration: Expected around 2025 for certain formulations.
- Biosimilar competition: No biosimilar drugs currently available; potential entry after patent expiry could result in 30-50% price reductions.
Regulatory and Policy Impact
- The FDA’s approval of Lenvima in new indications (such as endometrial carcinoma in 2021) has expanded market potential but may temporarily stabilize pricing due to high demand.
- Bulk purchasing agreements and insurance negotiations strongly influence net prices for health systems.
Summary of Key Market Insights
- Lenvatinib is a preferred multikinase inhibitor for specific cancers, with a global market nearing USD 3 billion in 2022.
- Market growth hinges on expanding indications and combination therapy approvals.
- Price projections suggest moderate decreases driven by competition and patent expiration, with higher residual pricing in established markets.
- Biosimilar entry post-2025 could significantly alter the pricing landscape.
Key Takeaways
- The drug maintains a premium price position due to multiple indications but faces downward pressure from patent cliffs.
- Market expansion into new indications offers growth but may involve pricing negotiations.
- Competitive landscape influences future pricing trends, especially after patent exclusivity ends.
- Price sensitivity remains high in emerging markets, where discounts of 20-30% are common.
FAQs
1. What are the primary competitors of Lenvatinib?
Sorafenib, Pazopanib, Regorafenib, and cabozantinib are key competitors in renal cell carcinoma and hepatocellular carcinoma.
2. How does Lenvatinib’s price compare to similar drugs?
Its list price is higher than many competitors due to broader indications and perceived efficacy; typical annual costs range from $50,000 to $70,000.
3. When will patent expiration likely influence pricing?
Patent expiry is anticipated around 2025, which may enable biosimilar entry and significant price reductions.
4. How do regulatory approvals impact the market?
New approvals, especially for additional indications such as endometrial carcinoma, expand the patient population, boosting sales and possibly maintaining higher prices.
5. What are the main factors affecting future prices?
Patent status, competition, clinical adoption, and healthcare policies are key determinants of future pricing trends.
Sources:
[1] FDA approval documents, 2015–2022.
[2] Market research reports (e.g., IQVIA, EvaluatePharma, 2022).
[3] Company financial disclosures and public statements.
